Table 2 Top six indications and top five concomitant drugs in adverse events reports of Lanreotide and octreotide.
Lanreotide | n(%) | Octreotide | n(%) | |
|---|---|---|---|---|
Indications | NeuroendocrineTumour | 2732(35.6) | NeuroendocrineTumour | 4987(27.34) |
acromegaly | 2008(26.16) | CarcinoidTumour | 2902(15.91) | |
CarcinoidTumour | 1252(16.31) | acromegaly | 2429(13.32) | |
NeoplasmMalignant | 196(2.55) | NeoplasmMalignant | 313(1.72) | |
PituitaryTumour | 93(1.21) | diarrhoea | 237(1.3) | |
congenital cystic kidney disease | 26(0.34) | PituitaryTumour | 189(1.04) | |
Concomitant medication | metformin | 340 | levothyroxine sodium | 634 |
levothyroxine sodium | 268 | metformin | 650 | |
vitamin d | 191 | cabergoline | 392 | |
amlodipine | 180 | furosemide | 391 | |
aspirin | 263 | hydrochlorothiazide | 752 |
